4.7 Review

Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis

Journal

JOURNAL OF AUTOIMMUNITY
Volume 80, Issue -, Pages 10-27

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2017.03.011

Keywords

Immunocompromised; Vaccine; Guideline

Categories

Funding

  1. Vifor Pharma
  2. Roche
  3. BMS
  4. GSK
  5. LFB
  6. Medimmune
  7. Novartis
  8. Pfizer
  9. Sanofi
  10. UCB-Pharma
  11. SOBI
  12. Gilead Sciences
  13. Astellas
  14. Merck
  15. MSD
  16. Hospira
  17. Theradiag
  18. Abbvie
  19. Janssen
  20. Takeda
  21. Genentech
  22. Mitsubishi
  23. Ferring
  24. Norgine
  25. Tillots
  26. Vifor
  27. Therakos
  28. Pharmacosmos
  29. Pilege
  30. Celltrion
  31. Biogaran
  32. Boerhinger-Ingelheim
  33. Lilly
  34. HAC-Pharma
  35. Index Pharmaceuticals
  36. Amgen
  37. Sandoz
  38. Forward Pharma GmbH
  39. Celgene
  40. Astra-Zeneca

Ask authors/readers for more resources

Background: Immunosuppressed patients are at risk of severe viral infections-related complications. National and international vaccination guidelines have been developed to decrease the mortality risk associated with these infections. However, a summary of these guidelines and the value of immunisation in this population is missing. Objectives: To summarize specific guidelines regarding vaccination in immunosuppressed patients. Methods: We performed a literature search based on last update vaccine guidelines in immunosuppressed adult patients published between 1/1/2005-1/31/2016 in English or French language using PubMed, Cochrane and Embase, as well as relevant medical society websites. Results: Of the 389 citations identified, 12 guidelines were selected Three additional guidelines were selected by searching on the websites from medical societies of each specialty. 15 guidelines were included, involving 19 medical societies issued from the US (n = 6), international collaboration (n = 3), UK (n = 2), Canada (n = 1), Australia (n = 1), France (n = 1), and Germany (n = 1). These guidelines provide recommendations on vaccination in asplenic patients (n = 5), cancer patients (n = 4), HIV patients (n = 5), hematopoietic stem cell recipients (n = 4), inflammatory bowel diseases patients (n = 5), psoriasis patients (n = 4), primary immunocompromised patients (n = 3), inflammatory rheumatic diseases patients (n = 6), and solid organ transplant recipients (n = 5). All guidelines recommended pneumococcal and injectable influenza vaccines. Other inactivated vaccines were recommended only in high risk patients. Live vaccines were usually contraindicated in patients under immunosuppressive therapy and/or in HIV patients with a CD4 count under 200/mm(3). Conclusion: Pneumococcal and injectable influenza are the two essential vaccines recommended in all immunocompromised patients. Other inactivated vaccines are only indicated in high risk patients. Live vaccines are usually contraindicated. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available